cabergoline has been researched along with Fatigue in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Ebashi, R; Koguchi, M; Masuoka, J; Nakahara, Y; Ogata, A; Shimokawa, S | 1 |
| Athanasoulia, AP; Brockhaus, AC; Ising, M; Sievers, C; Stalla, GK; Uhr, M; Yassouridis, A | 1 |
2 other study(ies) available for cabergoline and Fatigue
| Article | Year |
|---|---|
Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
Topics: Adult; Anticonvulsants; Cabergoline; Dopamine Agonists; Fatigue; Frontal Lobe; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Status Epilepticus; Thyroxine; Treatment Outcome; Vision Disorders | 2019 |
Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas.
Topics: Adult; Aged; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding Cassette Transporters; Cabergoline; Case-Control Studies; Ergolines; Fatigue; Female; Headache; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pituitary Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prolactinoma; Treatment Outcome | 2012 |